Publications searcher

The science produced by our scientists is very important. In 2024, 1,501 papers were published in scientific journals with an average impact factor of over 7.13 points.

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer.

PMID: 31260835
Journal: Journal of Thoracic Oncology
Year: 2019
Reference: J Thorac Oncol. 2019 Oct;14(10):1828-1838. doi: 10.1016/j.jtho.2019.06.021. Epub 2019 Jun 28.
Impact factor: 12.46
Publication type: Paper in international publication
Authors: Dhar, Arindam, Govindan, Ramaswamy, Ballas, Marc S, Mohammad, Helai P, Collingwood, Therese, Bauer, Todd M, Besse, Benjamin, Martinez-Marti, Alex, Trigo, Jose Manuel, Moreno, Victor et al.
DOI: 10.1016/j.jtho.2019.06.021

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer.

PMID: 31260835
Journal: Journal of Thoracic Oncology
Year: 2019
Reference: J Thorac Oncol. 2019 Oct;14(10):1828-1838. doi: 10.1016/j.jtho.2019.06.021. Epub 2019 Jun 28.
Impact factor:
Publication type: Paper in international publication
Authors: Ballas, Marc S; Bauer, Todd M; Besse, Benjamin; Collingwood, Therese; Dhar, Arindam; Ferron-Brady, Geraldine; Garrido, Pilar; Govindan, Ramaswamy; Kruger, Ryan G; Martinez-Marti, Alex et al.
DOI: 10.1016/j.jtho.2019.06.021

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

PMID: 30624604
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 Jun 1;30(6):1020. doi: 10.1093/annonc/mdy532.
Impact factor: 14.196
Publication type: Letter or abstract
Authors: Andreis, D De, Ropert, S, Lopez, E, Catteau, A, James, J, Marier, J-F, Beliveau, M, Martell, R E, Baselga, J, Armand, J-P et al.
DOI: 10.1093/annonc/mdy532

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

PMID: 30624604
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 Jun 1;30(6):1020. doi: 10.1093/annonc/mdy532.
Impact factor:
Publication type: Letter or abstract
Authors: Andreis, D De; Armand, J-P; Baselga, J; Beliveau, M; Catteau, A; Cortes, J; James, J; Lopez, E; Marier, J-F; Martell, R E et al.
DOI: 10.1093/annonc/mdy532

Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine-kinase inhibitor refractory gastrointestinal stromal tumors.

PMID: 31471313
Journal: CLINICAL CANCER RESEARCH
Year: 2019
Reference: Clin Cancer Res. 2019 Dec 15;25(24):7287-7293. doi: 10.1158/1078-0432.CCR-19-2150. Epub 2019 Aug 30.
Impact factor: 8.911
Publication type: Paper in international publication
Authors: Barysauskas, Constance M, Phallen, Jillian, Triplett, Olivia, Marino-Enriquez, Adrian, Wagner, Andrew J, Demetri, George D, Velculescu, Victor E, Paweletz, Cloud P, Fletcher, Jonathan A, George, Suzanne et al.
DOI: 10.1158/1078-0432.CCR-19-2150

Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine-kinase inhibitor refractory gastrointestinal stromal tumors.

PMID: 31471313
Journal: CLINICAL CANCER RESEARCH
Year: 2019
Reference: Clin Cancer Res. 2019 Dec 15;25(24):7287-7293. doi: 10.1158/1078-0432.CCR-19-2150. Epub 2019 Aug 30.
Impact factor:
Publication type: Paper in international publication
Authors: Barysauskas, Constance M; Demetri, George D; Fletcher, Jonathan A; George, Suzanne; Kuang, Yanan; Leal, Alessandro; Marino-Enriquez, Adrian; Morgan, Jeffrey A; Paweletz, Cloud P; Phallen, Jillian et al.
DOI: 10.1158/1078-0432.CCR-19-2150

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

PMID: 30770348
Journal: CLINICAL CANCER RESEARCH
Year: 2019
Reference: Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740. Epub 2019 Feb 15.
Impact factor: 8.911
Publication type: Paper in international publication
Authors: Jung, Kyung Hae, LoRusso, Patricia M, Burris, Howard A, Gordon, Michael S, Bang, Yung-Jue, Hellmann, Matthew D, Cervantes, Andres, Ochoa de Olza, Maria, Marabelle, Aurelien, Hodi, F Stephen et al.
DOI: 10.1158/1078-0432.CCR-18-2740

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

PMID: 30770348
Journal: CLINICAL CANCER RESEARCH
Year: 2019
Reference: Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740. Epub 2019 Feb 15.
Impact factor:
Publication type: Paper in international publication
Authors: Ahn, Myung-Ju; Bang, Yung-Jue; Barlesi, Fabrice; Burris, Howard A; Calvo, Emiliano; Cervantes, Andres; Davis, S Lindsey; Emens, Leisha A; Gordon, Michael S; Hamid, Omid et al.
DOI: 10.1158/1078-0432.CCR-18-2740

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.

PMID: 30679100
Journal: Clinical Breast Cancer
Year: 2019
Reference: Clin Breast Cancer. 2019 Apr;19(2):105-112. doi: 10.1016/j.clbc.2018.12.012. Epub 2018 Dec 20.
Impact factor: 2.762
Publication type: Paper in international publication
Authors: Ortega, Vanesa, Anton, Antonio, Garau, Isabel, Afonso, Noemia, Calvo, Lourdes, Fernandez, Yolanda, Martinez-Garcia, Maria, Blanco, Esperanza, Zamora, Pilar, Garcia, Mirta et al.
DOI: 10.1016/j.clbc.2018.12.012

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.

PMID: 30679100
Journal: Clinical Breast Cancer
Year: 2019
Reference: Clin Breast Cancer. 2019 Apr;19(2):105-112. doi: 10.1016/j.clbc.2018.12.012. Epub 2018 Dec 20.
Impact factor:
Publication type: Paper in international publication
Authors: Afonso, Noemia; Aguirre, Elena; Anton, Antonio; Blanco, Esperanza; Calvo, Lourdes; Cortes, Javier; Fernandez, Yolanda; Garau, Isabel; Garcia, Mirta; Illarramendi, Jose Juan et al.
DOI: 10.1016/j.clbc.2018.12.012

Phase II randomized study of radiotherapy and three-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients.

PMID: 30321689
Journal: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Year: 2019
Reference: Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):344-352. doi: 10.1016/j.ijrobp.2018.10.005. Epub 2018 Oct 12.
Impact factor: 6.203
Publication type: Paper in international publication
Authors: Mendez, Ma Jose, Maroto, Pablo, Luque, Raquel, de Portugal, Teresa, Aldabo, Ramon, Bonfill, Teresa, Morales-Barrera, Rafael, Garcia, Jose, Macia, Sonia, Maldonado, Xavier et al.
DOI: 10.1016/j.ijrobp.2018.10.005

Phase II randomized study of radiotherapy and three-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients.

PMID: 30321689
Journal: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Year: 2019
Reference: Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):344-352. doi: 10.1016/j.ijrobp.2018.10.005. Epub 2018 Oct 12.
Impact factor:
Publication type: Paper in international publication
Authors: Aldabo, Ramon; Bellmunt, Joaquim; Bonfill, Teresa; Carles, Joan; de Portugal, Teresa; Domenech, Montserrat; Figols, Mariona; Font, Albert; Foro, Palmira; Gallardo, Enrique et al.
DOI: 10.1016/j.ijrobp.2018.10.005

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR study.

PMID: 29794066
Journal: ONCOLOGIST
Year: 2019
Reference: Oncologist. 2019 Jan;24(1):38-46. doi: 10.1634/theoncologist.2017-0622. Epub 2018 May 23.
Impact factor: 5.252
Publication type: Paper in international publication
Authors: Capdevila, Jaume, Teule, Alexandre, Barriuso, Jorge, Castellano, Daniel, Lopez, Carlos, Manzano, Jose Luis, Alonso, Vicente, Garcia-Carbonero, Rocio, Dotor, Emma, Matos, Ignacio et al.
DOI: 10.1634/theoncologist.2017-0622

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR study.

PMID: 29794066
Journal: ONCOLOGIST
Year: 2019
Reference: Oncologist. 2019 Jan;24(1):38-46. doi: 10.1634/theoncologist.2017-0622. Epub 2018 May 23.
Impact factor:
Publication type: Paper in international publication
Authors: Alonso, Vicente; Barriuso, Jorge; Capdevila, Jaume; Casanovas, Oriol; Castellano, Daniel; Custodio, Ana; Dotor, Emma; Garcia-Carbonero, Rocio; Lopez, Carlos; Manzano, Jose Luis et al.
DOI: 10.1634/theoncologist.2017-0622

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.

PMID: 30840064
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 May 1;30(5):796-803. doi: 10.1093/annonc/mdz082.
Impact factor: 14.196
Publication type: Paper in international publication
Authors: Robles-Diaz, L, Garcia-Alfonso, P, Buges, C, Duran, G, Salud, A, Navarro, V, Capella, G, Salazar, R, Aranda, E, Valladares, M et al.
DOI: 10.1093/annonc/mdz082

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.

PMID: 30840064
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 May 1;30(5):796-803. doi: 10.1093/annonc/mdz082.
Impact factor:
Publication type: Paper in international publication
Authors: Aranda, E; Azuara, D; Buges, C; Capella, G; Duran, G; Elez, E; Falco, E; Garcia-Alfonso, P; Lopez-Lopez, C; Navarro, V et al.
DOI: 10.1093/annonc/mdz082

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.

PMID: 30523748
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2019
Reference: J Clin Oncol. 2019 Feb 10;37(5):367-374. doi: 10.1200/JCO.18.00053. Epub 2018 Dec 4.
Impact factor: 28.245
Publication type: Paper in international publication
Authors: Wease, Stephen, Blackwell, Beth, Valcarcel, David, Frassoni, Francesco, Boelens, Jaap Jan, Nierkens, Stefan, Jagasia, Madan, Wagner, John E, Kuball, Jurgen, Koh, Liang Piu et al.
DOI: 10.1200/JCO.18.00053

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.

PMID: 30523748
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2019
Reference: J Clin Oncol. 2019 Feb 10;37(5):367-374. doi: 10.1200/JCO.18.00053. Epub 2018 Dec 4.
Impact factor:
Publication type: Paper in international publication
Authors: Blackwell, Beth; Boelens, Jaap Jan; Cilloni, Daniela; Frassoni, Francesco; Freedman, Laurence S; Hanna, Rabi; Horwitz, Mitchell E; Hwang, William Y K; Jagasia, Madan; Koh, Liang Piu et al.
DOI: 10.1200/JCO.18.00053

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

PMID: 30624616
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 Jun 1;30(6):1017. doi: 10.1093/annonc/mdy529.
Impact factor: 14.196
Publication type: Letter or abstract
Authors: Baselga, J, Manikhas, A, Cortes, J, Roman, L, Semiglazov, V F, Byakhov, M, Lokanatha, D, Forenza, S, Goldfarb, R H, Matera, J et al.
DOI: 10.1093/annonc/mdy529

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

PMID: 30624616
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 Jun 1;30(6):1017. doi: 10.1093/annonc/mdy529.
Impact factor:
Publication type: Letter or abstract
Authors: Azarnia, N; Baselga, J; Byakhov, M; Cortes, J; Forenza, S; Goldfarb, R H; Hudis, C A; Llombart, A; Lokanatha, D; Manikhas, A et al.
DOI: 10.1093/annonc/mdy529

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.

PMID: 30817251
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2019
Reference: J Clin Oncol. 2019 May 1;37(13):1051-1061. doi: 10.1200/JCO.18.02031. Epub 2019 Feb 28.
Impact factor: 28.245
Publication type: Paper in international publication
Authors: Heery, Christopher R, Gulley, James L, Borre, Michael, Vogelzang, Nicholas J, Ng, Siobhan, Agarwal, Neeraj, Parker, Chris C, Pook, David W, Rathenborg, Per, Flaig, Thomas W et al.
DOI: 10.1200/JCO.18.02031

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.

PMID: 30817251
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2019
Reference: J Clin Oncol. 2019 May 1;37(13):1051-1061. doi: 10.1200/JCO.18.02031. Epub 2019 Feb 28.
Impact factor:
Publication type: Paper in international publication
Authors: Agarwal, Neeraj; Borre, Michael; Carles, Joan; Chen, Liddy; Flaig, Thomas W; Gerritsen, Winald R; Gulley, James L; Heery, Christopher R; Kantoff, Philip W; Langkilde, Niels C et al.
DOI: 10.1200/JCO.18.02031

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.

PMID: 30523758
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2019
Reference: J Clin Oncol. 2019 Jan 20;37(3):230-238. doi: 10.1200/JCO.18.00089. Epub 2018 Dec 4.
Impact factor: 28.245
Publication type: Paper in international publication
Authors: Macarulla, Teresa, Pazo-Cid, Roberto, Guillen-Ponce, Carmen, Lopez, Rafael, Vera, Ruth, Reboredo, Margarita, Munoz Martin, Andres, Rivera, Fernando, Diaz Beveridge, Roberto, La Casta, Adelaida et al.
DOI: 10.1200/JCO.18.00089

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.

PMID: 30523758
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2019
Reference: J Clin Oncol. 2019 Jan 20;37(3):230-238. doi: 10.1200/JCO.18.00089. Epub 2018 Dec 4.
Impact factor:
Publication type: Paper in international publication
Authors: Ales, Immaculada; Diaz Beveridge, Roberto; Guillen-Ponce, Carmen; Hidalgo, Manuel; La Casta, Adelaida; Lopez, Rafael; Macarulla, Teresa; Martin Valades, Jose; Martinez-Galan, Joaquina; Munoz Martin, Andres et al.
DOI: 10.1200/JCO.18.00089

Publications

Publications searcher

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer.

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer.

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine-kinase inhibitor refractory gastrointestinal stromal tumors.

Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine-kinase inhibitor refractory gastrointestinal stromal tumors.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.

Phase II randomized study of radiotherapy and three-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients.

Phase II randomized study of radiotherapy and three-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients.

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR study.

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR study.

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.

Patronage:

Collaborating:

Accreditations: